AR053730A1 - Derivados de (sulfamoil-alquil)-amida de acido heteroaril-carboxilico como inhibidores del factor xa - Google Patents

Derivados de (sulfamoil-alquil)-amida de acido heteroaril-carboxilico como inhibidores del factor xa

Info

Publication number
AR053730A1
AR053730A1 ARP060102004A ARP060102004A AR053730A1 AR 053730 A1 AR053730 A1 AR 053730A1 AR P060102004 A ARP060102004 A AR P060102004A AR P060102004 A ARP060102004 A AR P060102004A AR 053730 A1 AR053730 A1 AR 053730A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkylene
substituted
mono
heterocyclyl
Prior art date
Application number
ARP060102004A
Other languages
English (en)
Spanish (es)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR053730A1 publication Critical patent/AR053730A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP060102004A 2005-05-20 2006-05-18 Derivados de (sulfamoil-alquil)-amida de acido heteroaril-carboxilico como inhibidores del factor xa AR053730A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05010929A EP1724269A1 (en) 2005-05-20 2005-05-20 Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide - derivatives as factor Xa inhibitors

Publications (1)

Publication Number Publication Date
AR053730A1 true AR053730A1 (es) 2007-05-16

Family

ID=35116052

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102004A AR053730A1 (es) 2005-05-20 2006-05-18 Derivados de (sulfamoil-alquil)-amida de acido heteroaril-carboxilico como inhibidores del factor xa

Country Status (25)

Country Link
US (1) US8088925B2 (cg-RX-API-DMAC7.html)
EP (2) EP1724269A1 (cg-RX-API-DMAC7.html)
JP (1) JP5027802B2 (cg-RX-API-DMAC7.html)
KR (1) KR101373533B1 (cg-RX-API-DMAC7.html)
CN (1) CN101180296B (cg-RX-API-DMAC7.html)
AR (1) AR053730A1 (cg-RX-API-DMAC7.html)
AT (1) ATE452133T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006246669B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0610320A2 (cg-RX-API-DMAC7.html)
CA (1) CA2609288C (cg-RX-API-DMAC7.html)
DE (1) DE602006011156D1 (cg-RX-API-DMAC7.html)
DK (1) DK1888567T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2006000119A (cg-RX-API-DMAC7.html)
ES (1) ES2338151T3 (cg-RX-API-DMAC7.html)
GT (1) GT200600211A (cg-RX-API-DMAC7.html)
IL (1) IL187430A (cg-RX-API-DMAC7.html)
MX (1) MX2007014274A (cg-RX-API-DMAC7.html)
MY (1) MY150693A (cg-RX-API-DMAC7.html)
PA (1) PA8675301A1 (cg-RX-API-DMAC7.html)
PE (1) PE20061452A1 (cg-RX-API-DMAC7.html)
PT (1) PT1888567E (cg-RX-API-DMAC7.html)
SV (1) SV2007002534A (cg-RX-API-DMAC7.html)
TW (1) TWI376377B (cg-RX-API-DMAC7.html)
UY (1) UY29550A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006122661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012149102A1 (en) * 2011-04-29 2012-11-01 Glaxosmithkline Llc Novel compounds as wip1 inhibitors
EP3078378B1 (en) 2015-04-08 2020-06-24 Vaiomer Use of factor xa inhibitors for regulating glycemia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA953361B (en) 1994-04-26 1996-01-12 Selectide Corp Factor Xa inhibitors
GB0030305D0 (en) * 2000-12-13 2001-01-24 Lilly Co Eli Compounds
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
HUP0304058A2 (hu) * 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
DE10254336A1 (de) * 2002-11-21 2004-06-03 Merck Patent Gmbh Carbonsäureamide
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
AU2003292218A1 (en) * 2002-12-23 2004-07-14 Sanofi-Aventis Deutschland Gmbh PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
EP1590327A1 (en) * 2002-12-23 2005-11-02 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
EP1479678A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Pyrazole-derivatives as factor xa inhibitors
TW200510311A (en) * 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
DE10322469A1 (de) * 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Also Published As

Publication number Publication date
AU2006246669A1 (en) 2006-11-23
ES2338151T3 (es) 2010-05-04
EP1888567B1 (en) 2009-12-16
GT200600211A (es) 2007-02-05
CA2609288C (en) 2014-01-21
DK1888567T3 (da) 2010-04-19
KR101373533B1 (ko) 2014-03-12
PA8675301A1 (es) 2006-12-07
TWI376377B (en) 2012-11-11
IL187430A (en) 2013-06-27
BRPI0610320A2 (pt) 2010-06-15
PE20061452A1 (es) 2007-01-16
SV2007002534A (es) 2007-02-19
WO2006122661A1 (en) 2006-11-23
US20080167346A1 (en) 2008-07-10
MX2007014274A (es) 2008-01-22
KR20080015800A (ko) 2008-02-20
US8088925B2 (en) 2012-01-03
IL187430A0 (en) 2008-02-09
UY29550A1 (es) 2006-12-29
TW200716620A (en) 2007-05-01
EP1724269A1 (en) 2006-11-22
EP1888567A1 (en) 2008-02-20
HK1117157A1 (en) 2009-01-09
DE602006011156D1 (de) 2010-01-28
AU2006246669B2 (en) 2011-10-06
DOP2006000119A (es) 2006-11-30
ATE452133T1 (de) 2010-01-15
MY150693A (en) 2014-02-28
PT1888567E (pt) 2010-02-09
CN101180296B (zh) 2011-10-19
JP2008540589A (ja) 2008-11-20
CN101180296A (zh) 2008-05-14
CA2609288A1 (en) 2006-11-23
JP5027802B2 (ja) 2012-09-19

Similar Documents

Publication Publication Date Title
AR070441A1 (es) Clorotiofeno - amidas como inhibidores de los factores de coagulacion xa y trombina
AR061599A1 (es) Nitrilos espirociclicos como inhibidores de proteasa
ES2930585T3 (es) Inhibidores de TYK2 y usos de los mismos
ES2930198T3 (es) Inhibidores de TYK2 y usos de los mismos
TWI840332B (zh) Tyk2抑制劑及其用途
JP2009509989A5 (cg-RX-API-DMAC7.html)
ES2381890T3 (es) Compuesto de imidazo[4,5-c]piridina y métodos de tratamiento antiviral
AU2012314498B2 (en) Viral replication inhibitors
ES2883274T3 (es) Moduladores heterocíclicos de la síntesis de lípidos
AU2021240046A1 (en) MDM2 degraders and uses thereof
ES2651688T3 (es) Métodos y composiciones para la reanimación hipotensiva
AR033617A1 (es) Compuestos derivados espirociclicos, metodos para prepararlos y su uso como inhibidores de fosfodiesterasa-7
AR034292A1 (es) Compuesto de piperazina azoindoloxoacetica sustituido, formulacion farmaceutica que lo comprende y su uso para preparar dicha formulacion
CA2945819A1 (en) Irak inhibitors and uses thereof
JP2013542960A (ja) 脂肪酸シンターゼ阻害剤
KR20250031189A (ko) 아닐리노-피라졸 유도체, 이의 조성물 및 방법
WO2023205475A1 (en) Ctps1 inhibitors and uses thereof
SI8810183A8 (sl) Postopek za pridobivanje kristalne natrijeve soli 5-klor-3-(2-tenoil)-2-oksindol-1-karboksamida
JP2023110094A (ja) Tcr-nck相互作用の阻害剤としてのクロメン誘導体
AR049346A1 (es) 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas
JP2010503625A5 (cg-RX-API-DMAC7.html)
WO2024229393A1 (en) Hpk1 degraders and uses thereof
AR045683A1 (es) Derivados de bencimidazol como inhibidores del factor xa
BRPI0717536A2 (pt) Composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal do mesmo, e, método de tratamento de uma infecção por rsv em um indivíduo em necessidade do mesmo
JP2010503624A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal